

INFORMATION DISCLOSURE CITATION

Atty. Docket No.: 03804.1129-00000	
Applicant: Jean-Francois DEDIEU et al.	Serial No.: Unassigned
Filing Date: August 31, 2000	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date	Name	Class	Sub Class	Filing Date (if appropriate)
D	1	4,939,088	07/1990	Young et al.	435	320.1	
J	2	5,194,601	03/1993	Sugden et al.	435	320.1	
J	3	5,672,344	09/30/97	Kelley et al.	424	172.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
D	4	WO 92/05262	4/1992	WIPO			
J	5	WO 93/19191	3/1993	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

D	6	Clayman et al., "Adeno p53 Gene Transfer in a Phase I/II Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma," Soc. for Biol. Therapy, Ann. Meeting, Abstract (1996)
J	7	Clayman et al., "Adenovirus Mediated p53 Gene Transfer in a Phase I Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma," ASCO Annual Meeting, Abstract (1997)
J	8	Clayman et al., "Adenovirus Mediated p53 Gene Transfer in Patient with Advanced Recurrent Head and Neck Squamous Carcinoma," AACR Annual Meeting, Abstract
J	9	Clayman et al., "Gene Therapy for Head and Neck Cancer: Comparing the Tumor Suppressor Gene p53 and a Cell Cycle Regulator WAF1/CIP1 (p21)," Arch. Otolaryngol. Head Neck Surgery, Vol. 122, pp. 489-493 (1996)

Examiner: D	Date Considered: 5/17/02
* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-1449 Patent and Trademark Office - U.S. Department of Commerce	

<i>On</i>	10	Coghlan, "New Scientist," Vol. 149, pp. 14-15 (1995)
<i>On</i>	11	Crystal, "Transfer of genes to humans: early lessons and obstacles to success," Science Vol. 270, pp. 404-409 (1995)
	12	Dong et al., "Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus," Human Gene Therapy Vol. 7, pp. 319-331 (1996)
	13	Karlsson, "Treatment of genetic defects in hematopoietic cell function by gene transfer," Blood, Vol. 78, No. 10, pp. 2481-2492 (1991)
	14	Kozarsky et al., "Gene therapy: adenovirus vectors," Current Opinion on Genetics and Development, Vol. 3, pp. 499-503 (1996)
	15	Marshall, "Gene therapy's growing pains," Science, Vol. 269, pp. 1050-1055 (1995)
	16	Marshall, "Less hype, more biology needed for gene therapy," Science, Vol. 270, p. 1751 (1995)
	17	Marx, "Cell death studies yield cancer clues," Science, Vol. 259, pp. 760-761 (1996)
	18	Mastrangeli et al., "Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer," The Journal of Clinical Investigation, Vol. 91, pp. 225-234 (1993)
	19	Morsy et al., "Progress toward human gene therapy," JAMA, Vol. 270, No. 19, pp. 2338-2345 (1993)
	20	Orkin & Moltulsky, NIH Report on Gene Therapy, (Dec. 7, 1995)
	21	Perricaudet et al., Ann. Oncol., Vol. 3, Suppl. 5, p. 135 (1992)
	22	Roth et al., "Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer," Nature Medicine, Vol. 2, pp. 985-991 (1996)
	23	Sugden et al., "A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection," Journal of Virology, pp. 2644-2649 (1989)
	24	Swisher et al., "Persistent Transgene Expression Following Repeated Injections of a Recombinant Adenovirus Containing the p53 Wild-Type Gene in Patients with Non-Small Cell Lung Cancer," AACR Annual Meeting, Abstract
	25	Swisher et al., "Adenoviral Mediated p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)," ASCO Annual Meeting, Abstract (1997)
<i>On</i>	26	Zimber-Strobl et al., "Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene," Journal of Virology pp. 415-423 (1991)

Examiner:	<i>Dah</i>	Date Considered:	<i>5/17/02</i>
* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO-1449		Patent and Trademark Office - U.S. Department of Commerce	